497177-66-9

Basic information

• Product Name: 4-Piperidinamine, 1-(trifluoroacetyl)- (9CI)
• Synonyms: 4-Piperidinamine, 1-(trifluoroacetyl)- (9CI);1-(4-aminopiperidin-1-yl)-2,2,2-trifluoroethan-1-one;1-(4-AMINOPIPERIDIN-1-YL)-2,2,2-TRIFLUOROETHANONE
• CAS NO: 497177-66-9
• Molecular Formula: C₇H₁₁F₃N₂O
• Molecular Weight: 196.1702496
• Product Categories: ACETYLHALIDE
• Mol File: 497177-66-9.mol
• Article Data: 1

Chemical Properties

• Appearance: /
• Storage Temp.: 2-8°C(protect from light)
• CAS DataBase Reference: 4-Piperidinamine, 1-(trifluoroacetyl)- (9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: 4-Piperidinamine, 1-(trifluoroacetyl)- (9CI)(497177-66-9)
• EPA Substance Registry System: 4-Piperidinamine, 1-(trifluoroacetyl)- (9CI)(497177-66-9)

Safety Data

• Hazardous Substances Data: 497177-66-9(Hazardous Substances Data)

Usage

Uses

1-(4-Aminopiperidin-1-yl)-2,2,2-trifluoroethanone is used as a reactant in the preparation of naphthyridinones and related compounds as antibacterial agents.

Upstream product

• 182223-54-7 piperidin-4-ylcarbamic acid benzyl ester 
• 87120-72-7 1-(tert-butoxycarbonyl)-4-aminopiperidine 
• 220394-97-8 4-(benzyloxycarbonylamino)-1-(tert-butoxycarbonyl)piperidine 

Relevant articles and documents

Discovery of 2-substituted 1H-benzo[d]immidazole-4-carboxamide derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors with in?vivo anti-tumor activity

Novel 1H-benzo[d]immidazole-4-carboxamide derivatives bearing five-membered or six-membered N-heterocyclic moieties at the 2-position were designed and synthesized as PARP-1 inhibitors. Structure-activity relationships were conducted and led to a number of potent PARP-1 inhibitors having IC50 values in the single or double digit nanomolar level. Some potent PARP-1 inhibitors also had similar inhibitory activities against PARP-2. Among all the synthesized compounds, compound 10a and 11e displayed strong potentiation effects on temozolomide (TMZ) in MX-1?cells (PF50?=?7.10, PF50?=?4.17). In?vivo tumor growth inhibition was investigated using compound 10a in combination with TMZ, and it was demonstrated that compound 10a could strongly potentiate the cytotoxicity of TMZ in MX-1 xenograft tumor model. Two co-crystal structures of compounds 11b and 15e complexed with PARP-1 were achieved and demonstrated a unique binding mode of these benzo-imidazole derivatives.